Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company... Show more
On June 26, 2025, the Stochastic Oscillator for DAWN moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 60 instances where the indicator left the oversold zone. In of the 60 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
The Aroon Indicator entered an Uptrend today. In of 123 cases where DAWN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Momentum Indicator moved below the 0 level on June 16, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on DAWN as a result. In of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for DAWN turned negative on June 18, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at .
DAWN moved below its 50-day moving average on June 10, 2025 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DAWN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
DAWN broke above its upper Bollinger Band on June 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.368) is normal, around the industry mean (16.377). P/E Ratio (0.000) is within average values for comparable stocks, (58.189). DAWN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (3.885) is also within normal values, averaging (252.527).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. DAWN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DAWN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
REQAX | 45.49 | 0.29 | +0.64% |
Russell Sustnbl Aware Eq A | |||
LAFVX | 19.93 | 0.12 | +0.61% |
Lord Abbett Affiliated R6 | |||
CRSSX | 9.53 | 0.02 | +0.23% |
Catholic Rspnsbl Invstmnts Small-Cap Ins | |||
QQMNX | 21.47 | -0.01 | -0.05% |
Federated Hermes MDT Market Neutral IS | |||
BKPIX | 59.54 | -0.09 | -0.15% |
ProFunds Banks UltraSector Inv |
A.I.dvisor indicates that over the last year, DAWN has been loosely correlated with OCUL. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if DAWN jumps, then OCUL could also see price increases.
Ticker / NAME | Correlation To DAWN | 1D Price Change % | ||
---|---|---|---|---|
DAWN | 100% | -0.15% | ||
OCUL - DAWN | 50% Loosely correlated | -2.54% | ||
DNLI - DAWN | 50% Loosely correlated | -2.69% | ||
IDYA - DAWN | 50% Loosely correlated | -4.13% | ||
SYRE - DAWN | 49% Loosely correlated | -4.99% | ||
RVMD - DAWN | 48% Loosely correlated | -1.52% | ||
More |